Cassina de Pecchi, Italy

Ferdinando C Giuliani

This inventor holds 2 USPTO granted patents. Top assignee: Boehringer Mannheim Italia. Active years: 1996-1998.


% Patents Active = 100.0

Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 5(Granted Patents)


Location History:

  • Cassina de Pecchi, IT (1996)
  • Monza, IT (1998)

Company Filing History:


Years Active: 1996-1998

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Ferdinando C Giuliani: Innovator in Antitumor Research

Introduction

Ferdinando C Giuliani is a notable inventor based in Cassina de Pecchi, Italy. He has made significant contributions to the field of antitumor research, holding 2 patents that reflect his innovative work. His research focuses on developing novel compounds with potential therapeutic applications.

Latest Patents

Giuliani's latest patents include "Trinuclear cationic platinum complexes having antitumor activity" and "6,9-bis[(2-aminoethyl) amino]benzo [g]isoquinoline-5,10-dione." In his pursuit of new heteroanalogs of anthracenediones, he identified 6,9-bis[(2-aminoethyl-amino]-benzo[g]isoquinoline-5,10-dione dimaleate (BBR 2778) as the most promising compound. Toxicological studies have indicated that BBR 2778 is not cardiotoxic, highlighting its potential as a safe therapeutic option.

Career Highlights

Giuliani is currently associated with Boehringer Mannheim Italia, where he continues to advance his research in the pharmaceutical field. His work has garnered attention for its innovative approach to cancer treatment.

Collaborations

Some of his notable coworkers include Mariella Valsecchi and Marco Conti, who have collaborated with him on various research projects.

Conclusion

Ferdinando C Giuliani's contributions to antitumor research through his patents and collaborations underscore his role as a significant innovator in the field. His work continues to pave the way for advancements in cancer therapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…